Final Answer:
The client is at risk for B. Bleeding, as evidenced by the client's A. Platelet count.
Step-by-step explanation:
The client receiving chemotherapy for breast cancer is at an increased risk of bleeding, and this is reflected in the diagnostic results, particularly the platelet count. In week 2, the platelet count has dropped to 100,000/mm³, which is below the normal range of 150,000 to 400,000/mm³. This significant decrease in platelet count indicates thrombocytopenia, a condition associated with an increased risk of bleeding. Platelets play a crucial role in blood clotting, and a low platelet count can lead to impaired clot formation, making the client vulnerable to bleeding.
The platelet count serves as a direct indicator of the client's risk for bleeding. Thrombocytopenia, as evidenced by the decreased platelet count in week 2, can result in spontaneous bleeding or increased bleeding following minor injuries or medical procedures. Monitoring the platelet count is essential in assessing the client's risk for bleeding and guiding interventions to prevent or manage potential bleeding complications. In this context, the platelet count is a key diagnostic parameter that informs the nurse about the client's hematological status and guides appropriate nursing interventions to minimize the risk of bleeding.